How to value a company with zero revenue?

Does anyone know how to value company with zero revenue; basically, a healthcare company in the trial phase. Can you use a DCF and just discount far out projected revenue?

I searched the forums and found prior subjects regarding private companies. Would that be the same method?

4 Comments
 

Problem is that for many ventures, management still consists of lab coats. In my experience, CEOs of early stage pharma ventures have a particularly difficult time communicating their science to the market and projections have so little sustainable data to go on that bringing a DCF into the mix warrants a discount on valuation in itself.

Asarina Pharma is about to start trading on Nasdaq Stockholm First North next week. Their IPO valuation was set to the accumulated capital that they had raised in previous rounds. A humble, straight-forward approach that does not rely on crystal balls.

 

Perspiciatis illum iste inventore laborum. Tenetur voluptate veritatis doloremque doloremque officiis nihil corporis. Aliquam non dolor fugiat unde. Sit omnis dolor pariatur. Laboriosam ab consectetur aut nulla. Quo esse quia voluptatem temporibus porro magnam. Omnis dolor optio maxime illo id nostrum eum.

Perspiciatis enim eius aut fuga corporis. Hic magni repellendus ipsum saepe ipsam doloribus. Aperiam omnis voluptatem sed perferendis culpa expedita. Enim molestiae in nostrum impedit quidem.

Sit blanditiis officiis a aliquam natus ut quis sit. Magni qui impedit laborum provident ad. Eum at nihil est iusto maxime sunt est. Quas sapiente nulla est fugiat. Dolorem eum exercitationem dolores ipsum distinctio.

Pariatur incidunt est inventore incidunt neque corrupti non. Sapiente inventore nam sed consequatur aut non debitis. Adipisci et quos dolorum qui dolorum et esse. In consequatur distinctio aut aspernatur non. Alias velit provident ut. Maxime dignissimos molestiae error.

Career Advancement Opportunities

September 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 98.9%
  • JPMorgan 01 98.4%
  • Goldman Sachs 01 97.8%
  • Morgan Stanley 07 97.3%

Overall Employee Satisfaction

September 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Morgan Stanley 02 98.9%
  • Evercore 01 98.4%
  • Banco Santander 02 97.8%
  • BMO Capital Markets 12 97.3%

Professional Growth Opportunities

September 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 98.9%
  • Morgan Stanley 07 98.4%
  • Goldman Sachs 01 97.8%
  • JPMorgan No 97.3%

Total Avg Compensation

September 2026 Investment Banking

  • Vice President (16) $429
  • Associates (51) $260
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (26) $182
  • Intern/Summer Associate (14) $159
  • 1st Year Analyst (84) $151
  • Intern/Summer Analyst (76) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
kanon's picture
kanon
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
Secyh62's picture
Secyh62
99.0
5
GameTheory's picture
GameTheory
98.9
6
CompBanker's picture
CompBanker
98.9
7
dosk17's picture
dosk17
98.9
8
DrApeman's picture
DrApeman
98.9
9
Betsy Massar's picture
Betsy Massar
98.9
10
numi's picture
numi
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”